LAIR-1 Suppresses Cell Growth of Ovarian Cancer Cell Via the PI3K-AKT-mTOR Pathway

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2020 Jul 7

PMID 32628130

Citations 14

Authors

Yan Liu

Li Ma

Fugen Shangguan

Xuena Zhao

Wenjie Wang

Zhiyue Gao

Huimin Zhou

Guiwu Qu

Yumei Huang

Jing An

Jiangnan Xue

Shude Yang

Qizhi Cao

Affiliations

Soon will be listed here.

Abstract

Recently, over-expression of LAIR-1 has been found in some solid cancers, including ovarian cancer. The role of LAIR-1 in cancer progression needs further investigation. In this study, we identified the LAIR-1 cDNA sequence of the ovarian cancer cells HO8910. Using SKOV3 cells, we confirmed the finding from our previous study that LAIR-1 could suppress in vitro cell proliferation and cell migration. We also found LAIR-1 overexpression can induce apoptosis of SKOV3 cells. We revealed LAIR-1 suppressed cell growth by inhibiting the PI3K-AKT-mTOR axis. Moreover, the LAIR-1 antitumor activity and its mechanism were also identified in vivo. We used Co-IP assay and mass spectrometry to identify potential LAIR-1-binding proteins in LAIR-1 overexpressing SKOV3 cells. MS analysis identified 167 potentially interacting proteins. GO analyses indicated a possible involvement of LAIR-1 in mRNA processing through its interaction with some eukaryotic translation initiation factors (eIF4E1B, eIF2S3, eIF3D, eIF4G2, eIF5B) and eukaryotic translation elongation factors (eEF1A2 and eEF1B2). Our findings suggest that LAIR-1 may suppress the growth of ovarian cancer cells by serving as a modulator that suppresses PI3K-AKT-mTOR directly or regulating protein synthesis at the translational level. Our results indicate that a LAIR-1-based strategy may prevent or suppress the progression of ovarian cancer.

Citing Articles

Mechanistic role of FN1 in LAIR-1 mediated downregulation of ovarian cancer cell proliferation.

Zhang H, Liu M, Zhong H, Ma L, Liu Y, Liu C BMC Cancer. 2025; 25(1):339.

PMID: 40000955 PMC: 11853514. DOI: 10.1186/s12885-025-13692-1.

Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment.

Carey K, Young C, Clark A, Dammer E, Singh R, Lillard Jr J J Ovarian Res. 2024; 17(1):240.

PMID: 39627836 PMC: 11613732. DOI: 10.1186/s13048-024-01556-4.

Extracellular matrix remodeling in the tumor immunity.

Du W, Xia X, Hu F, Yu J Front Immunol. 2024; 14:1340634.

PMID: 38332915 PMC: 10850336. DOI: 10.3389/fimmu.2023.1340634.

LAIR1 drives glioma progression by nuclear focal adhesion kinase dependent expressions of cyclin D1 and immunosuppressive chemokines/cytokines.

Wei X, Pan S, Wang Z, Chen J, Lu L, Cao Q Cell Death Dis. 2023; 14(10):684.

PMID: 37845206 PMC: 10579300. DOI: 10.1038/s41419-023-06199-9.

DSCC1 interacts with HSP90AB1 and promotes the progression of lung adenocarcinoma via regulating ER stress.

Lin X, Liu Y, Zhang H, Wu L, Li Q, Deng J Cancer Cell Int. 2023; 23(1):208.

PMID: 37742009 PMC: 10518103. DOI: 10.1186/s12935-023-03047-w.

References

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

Clark C, Gupta H, Sareddy G, Pandeswara S, Lao S, Yuan B . Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Res. 2016; 76(23):6964-6974. PMC: 5228566. DOI: 10.1158/0008-5472.CAN-16-0258. View

Poggi A, Tomasello E, Ferrero E, Zocchi M, Moretta L . p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor. Eur J Immunol. 1998; 28(7):2086-91. DOI: 10.1002/(SICI)1521-4141(199807)28:07<2086::AID-IMMU2086>3.0.CO;2-T. View

Musa J, Orth M, Dallmayer M, Baldauf M, Pardo C, Rotblat B . Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis. Oncogene. 2016; 35(36):4675-88. DOI: 10.1038/onc.2015.515. View

Revathidevi S, Munirajan A . Akt in cancer: Mediator and more. Semin Cancer Biol. 2019; 59:80-91. DOI: 10.1016/j.semcancer.2019.06.002. View

Chen X, Chen S, Xiu Y, Sun K, Zong Z, Zhao Y . RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression. Mol Cancer. 2015; 14:31. PMC: 4328068. DOI: 10.1186/s12943-015-0304-6. View

Ghoneum A, Said N . PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics. Cancers (Basel). 2019; 11(7). PMC: 6679095. DOI: 10.3390/cancers11070949. View

Verbrugge A, de Ruiter T, Geest C, Coffer P, Meyaard L . Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil differentiation and activation. J Leukoc Biol. 2006; 79(4):828-36. DOI: 10.1189/jlb.0705370. View

van der Vuurst de Vries A, Clevers H, Logtenberg T, Meyaard L . Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling. Eur J Immunol. 1999; 29(10):3160-7. DOI: 10.1002/(SICI)1521-4141(199910)29:10<3160::AID-IMMU3160>3.0.CO;2-S. View

10.

Migliaccio N, Sanges C, Ruggiero I, Martucci N, Rippa E, Arcari P . Raf kinases in signal transduction and interaction with translation machinery. Biomol Concepts. 2014; 4(4):391-9. DOI: 10.1515/bmc-2013-0003. View

11.

Ediriweera M, Tennekoon K, Samarakoon S . Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019; 59:147-160. DOI: 10.1016/j.semcancer.2019.05.012. View

12.

Zhu Y, Lei Q, Li D, Zhang Y, Jiang X, Hu Z . Proteomic and Biochemical Analyses Reveal a Novel Mechanism for Promoting Protein Ubiquitination and Degradation by UFBP1, a Key Component of Ufmylation. J Proteome Res. 2018; 17(4):1509-1520. DOI: 10.1021/acs.jproteome.7b00843. View

13.

Wu X, Zhang L, Zhou J, Liu L, Fu Q, Fu A . Clinicopathologic significance of LAIR-1 expression in hepatocellular carcinoma. Curr Probl Cancer. 2018; 43(1):18-26. DOI: 10.1016/j.currproblcancer.2018.04.005. View

14.

Dobbin Z, Landen C . The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013; 14(4):8213-27. PMC: 3645739. DOI: 10.3390/ijms14048213. View

15.

Yang L, Zhang M, Wu L, Mao L, Chen L, Yu G . LAIR-1 overexpression and correlation with advanced pathological grade and immune suppressive status in oral squamous cell carcinoma. Head Neck. 2018; 41(4):1080-1086. DOI: 10.1002/hed.25539. View

16.

Meyaard L, Hurenkamp J, Clevers H, Lanier L, Phillips J . Leukocyte-associated Ig-like receptor-1 functions as an inhibitory receptor on cytotoxic T cells. J Immunol. 1999; 162(10):5800-4. View

17.

Wang Y, Zhang X, Miao F, Cao Y, Xue J, Cao Q . Clinical significance of leukocyte-associated immunoglobulin-like receptor-1 expression in human cervical cancer. Exp Ther Med. 2017; 12(6):3699-3705. PMC: 5228450. DOI: 10.3892/etm.2016.3842. View

18.

Cao Q, Fu A, Yang S, He X, Wang Y, Zhang X . Leukocyte-associated immunoglobulin-like receptor-1 expressed in epithelial ovarian cancer cells and involved in cell proliferation and invasion. Biochem Biophys Res Commun. 2015; 458(2):399-404. DOI: 10.1016/j.bbrc.2015.01.127. View

19.

Zoncu R, Efeyan A, Sabatini D . mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2010; 12(1):21-35. PMC: 3390257. DOI: 10.1038/nrm3025. View

20.

Meyaard L . LAIR and collagens in immune regulation. Immunol Lett. 2009; 128(1):26-8. DOI: 10.1016/j.imlet.2009.09.014. View